Scarica l'app Stockscreener
15.65
1.46%
0.195
Precedente Chiudi:
$15.46
Aprire:
$16.02
Volume 24 ore:
1.21M
Relative Volume:
0.44
Capitalizzazione di mercato:
$1.98B
Reddito:
$631.73M
Utile/perdita netta:
$-239.78M
Rapporto P/E:
-7.75
EPS:
-2.02
Flusso di cassa netto:
$-33.45M
1 W Prestazione:
-10.22%
1M Prestazione:
-1.29%
6M Prestazione:
+50.60%
1 anno Prestazione:
+10.42%
Intervallo 1D:
$15.18
$16.03
Intervallo di 1 settimana:
$15.18
$18.38
Portata 52W:
$6.78
$20.34
10 X Genomics Inc Stock (TXG) Company Profile
Nome
10 X Genomics Inc
Settore
Industria
Telefono
(925) 401-7300
Indirizzo
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Confronta TXG con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
15.68 | 1.96B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
219.63 | 36.70B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
69.56 | 12.56B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
45.00 | 8.26B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
96.09 | 8.27B | 1.15B | 96.70M | -161.99M | 1.09 |
|
BTSG
Brightspring Health Services Inc
|
36.47 | 6.59B | 11.99B | 24.18M | 234.31M | 0.2956 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2025-12-02 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-09-11 | Iniziato | Piper Sandler | Neutral |
| 2025-02-13 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | Iniziato | Leerink Partners | Outperform |
| 2024-07-22 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-07-18 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-10 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-06-27 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-05-01 | Downgrade | TD Cowen | Buy → Hold |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-10 | Iniziato | Barclays | Overweight |
| 2023-03-31 | Iniziato | Stephens | Overweight |
| 2023-02-02 | Iniziato | UBS | Neutral |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-08-18 | Downgrade | Goldman | Neutral → Sell |
| 2022-07-25 | Iniziato | Canaccord Genuity | Buy |
| 2022-07-15 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-07-15 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-09-14 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-03-15 | Iniziato | William Blair | Outperform |
| 2020-12-02 | Iniziato | Goldman | Neutral |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-10 | Iniziato | Stifel | Buy |
| 2020-03-05 | Iniziato | Guggenheim | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-10-07 | Iniziato | BofA/Merrill | Buy |
| 2019-10-07 | Iniziato | Cowen | Outperform |
| 2019-10-07 | Iniziato | JP Morgan | Overweight |
| 2019-09-24 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
10 X Genomics Inc Borsa (TXG) Ultime notizie
10x Genomics $TXG Position Increased by Nikko Asset Management Americas Inc. - MarketBeat
Why The Narrative Around 10x Genomics Is Shifting After New Institutional Buying And Product Updates - Yahoo Finance
TXG: Citigroup Downgrades 10x Genomics to Neutral with $18 Price Target | TXG Stock News - GuruFocus
10x Genomics (TXG) Q2 2025 Earnings Transcript - The Motley Fool
10x Genomics (TXG) Stock: Citi Downgrade, AI Partnerships and 2026 Forecast After December 11 Sell-Off - ts2.tech
Why 10x Genomics (TXG) Stock Is Nosediving - Finviz
10x Genomics $TXG Shares Bought by Jump Financial LLC - MarketBeat
Life Sciences Tools & Services Stocks Q3 Earnings: 10x Genomics (NASDAQ:TXG) Firing on All Cylinders - Finviz
Why 10x Genomics Inc. stock appeals to analystsMarket Risk Summary & Long-Term Capital Growth Ideas - Newser
Russell Investments Group Ltd. Increases Stock Position in 10x Genomics $TXG - MarketBeat
Is 10x Genomics Inc. (1KJ) stock among top earnings playsJuly 2025 Highlights & Low Risk Entry Point Tips - Newser
Market Fear: Is CPSR stock trading at a premium valuation2025 Performance Recap & Fast Moving Stock Trade Plans - BỘ NỘI VỤ
10x Genomics Comments on Second UPC Preliminary Injunction Decis - GuruFocus
TXG: Morgan Stanley Downgrades 10x Genomics, Raises Price Target - GuruFocus
Tumor Transcriptomics Research Report 2025: An $8.71 Billion Market by 2030, Driven by Rising Global Cancer Prevalence and Advancements in Genomic Sequencing Technologies - GlobeNewswire Inc.
TXG Technical Analysis & Signals — Is 10x Genomics, Inc. Stock a Buy or Sell? - Meyka
Is 10x Genomics Inc. stock safe for conservative investors2025 Breakouts & Breakdowns & Weekly Return Optimization Alerts - BỘ NỘI VỤ
Aug Levels: Why 10x Genomics Inc. stock could benefit from AI revolutionJuly 2025 Institutional & Verified Technical Trade Signals - BỘ NỘI VỤ
What sentiment indicators say about 10x Genomics Inc. stockQuarterly Profit Summary & Reliable Breakout Forecasts - BỘ NỘI VỤ
10x Genomics to Acquire Scale Biosciences (PR Newswire) - Aktiellt
10x Genomics (TXG) Is Up 19.8% After Pan-Cancer Atlas Collaboration With Garvan and University of Tokyo - simplywall.st
Buy Signal: Is 10x Genomics Inc. stock safe for conservative investorsWeekly Earnings Recap & Reliable Momentum Entry Alerts - BỘ NỘI VỤ
How 10x Genomics Inc. stock responds to policy changes2025 Volatility Report & Risk Managed Trade Strategies - BỘ NỘI VỤ
10x Genomics Insider Sold Shares Worth $251,936, According to a Recent SEC Filing - marketscreener.com
[Form 4] 10x Genomics, Inc. Insider Trading Activity - Stock Titan
Pres Hindson Surrenders 8,283 Of 10X Genomics Inc [TXG] - TradingView
BrightSpring Health Services, 10x Genomics, QuidelOrtho, Medpace, and Fortrea Shares Are Soaring, What You Need To Know - Finviz
CEO Saxonov Files To Sell 13,096 Of 10X Genomics Inc [TXG] - TradingView
CFO Taich Files To Sell 11,312 Of 10X Genomics Inc [TXG] - TradingView
Q3 2025 10X Genomics Inc Earnings Call Transcript - GuruFocus
10x Genomics, Inc. (NASDAQ:TXG) Q4 2024 Earnings Call Transcript - MSN
10x Genomics, Inc.Common Stock (NQ: TXG - Markets Financial Content
Is 10x Genomics’ (TXG) New Asia-Pacific Consortium Key to Sustaining Its Leadership in Spatial Genomics? - Yahoo Finance
10x Genomics (TXG) Price Target Increased by 10.47% to 16.66 - MSN
Bruker, 10x Genomics, PacBio, ICU Medical, and Dentsply Sirona Shares Skyrocket, What You Need To Know - Yahoo Finance
10X Genomics stock hits 52-week high at 17.7 USD By Investing.com - Investing.com India
10X Genomics stock hits 52-week high at 17.7 USD - Investing.com
Spatial Biology Market Analysis and Forecast, 2025-2035: - GlobeNewswire
Spatial Biology Market Analysis and Forecast, 2025-2035: Stellaromics, RareCyte, and 10x Genomics Drive Innovation and Funding Momentum - Yahoo Finance
How 10x Genomics Inc. (1KJ) stock trades pre earnings2025 Support & Resistance & Reliable Breakout Forecasts - newser.com
Total liabilities & shareholders' equities of 10x Genomics Inc Class A – HAM:1KJ - TradingView
Is 10x Genomics Inc. stock a buy before product launchesJuly 2025 Closing Moves & Safe Entry Zone Tips - newser.com
New ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas Powered by 10x Genomics' Xenium - StreetInsider
10x Genomics (Nasdaq: TXG) Xenium Powers ASTRA Atlas of 2,000 Asia-Pacific Tumor Samples - Stock Titan
10x Genomics Expands Flex Lineup with High-Throughput Single-Cell Assay Launch - MSN
TXG (10x Genomics) Inventory-to-Revenue : 0.44 (As of Sep. 2025) - GuruFocus
10x Genomics Announces Chief Legal Officer Retirement - The Globe and Mail
10x Genomics GC Who Led Rule Of Law Effort To Retire In '26 - Law360
There's Reason For Concern Over 10x Genomics, Inc.'s (NASDAQ:TXG) Massive 42% Price Jump - simplywall.st
10x Genomics, Inc. Announces Executive Changes, Effective January 1, 2026 - MarketScreener
10X Genomics Stock Soars 17.31%, Hits Intraday High of $15.26 - Markets Mojo
10 X Genomics Inc Azioni (TXG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
10 X Genomics Inc Azioni (TXG) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hindson Benjamin J. | See Remarks |
Nov 24 '25 |
Sale |
19.00 |
8,283 |
157,363 |
432,605 |
| Saxonov Serge | Chief Executive Officer |
Nov 24 '25 |
Sale |
19.00 |
13,261 |
251,936 |
1,021,556 |
3.42%
2.49%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):